{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:14:51Z","timestamp":1767989691447,"version":"3.49.0"},"reference-count":33,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: Many biologic agents cause some degree of immunosuppression, which can increase the risk of reactivation of tuberculosis infection (TBI). This risk is variable between individual biologics. We aimed to assess current (and recommended) clinical practice of TBI screening and treatment among patients initiating treatment with biologic agents. Methods: An online questionnaire was distributed via email to members of the Global Tuberculosis Network and associated professional organisations to seek insights into the screening for and treatment of TBI in patients treated with biologics. Results: A total of 163 respondents in 27 countries answered at least one question. For all biologics described in the questionnaire, respondents advised increasing screening relative to current practice. Observed and supported TBI screening rates in patients treated with TNF-a inhibitors were high, especially for older TNF-a inhibitors. Most participants supported TBI screening in patients treated with B- or T-cell inhibitors but not in those treated with interleukin inhibitors. Guideline awareness was higher for TNF-a inhibitors than for other biologic classes (79% vs. 34%). Conclusions: Although respondents stated that TBI screening rates are lower than what they consider ideal, there was a tendency to recommend TBI screening in patients treated with biologics not known to be associated with an increased risk of TBI. As a result, there is a potential risk of over-screening and over-treatment of TBI, potentially causing harm, in patients treated with biologics other than TNF-a inhibitors. There is a need to research the risk of TBI associated with biologics and for guidelines to address the spectrum of TBI risk across all types of biologics.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20240082","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T15:49:49Z","timestamp":1726674589000},"page":"e20240082","source":"Crossref","is-referenced-by-count":4,"title":["Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent"],"prefix":"10.36416","author":[{"given":"Adiba","family":"Sultana1,2","sequence":"first","affiliation":[{"name":"1. University of New South Wales, Sydney, Australia. 2. The George Institute for Global Health, Sydney, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Battista Migliori3","sequence":"additional","affiliation":[{"name":"3. Istituti Clinici Scientifici Maugeri - IRCCS - Tradate, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia","family":"D\u2019Ambrosio,4","sequence":"additional","affiliation":[{"name":"4. Public Health Consulting Group, Lugano, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Mar\u00eda","family":"Garc\u00eda-Garc\u00eda5","sequence":"additional","affiliation":[{"name":"5. Tuberculosis Research Programme - PII-TB - Spanish Society of Pulmonology and Thoracic Surgery - SEPAR - Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Rossato Silva6","sequence":"additional","affiliation":[{"name":"6. Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Adrian Rendon5","sequence":"additional","affiliation":[{"name":"5. Tuberculosis Research Programme - PII-TB - Spanish Society of Pulmonology and Thoracic Surgery - SEPAR - Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"R Codecasa7","sequence":"additional","affiliation":[{"name":"7. Regional TB Reference Centre, Villa Marelli Inst, Niguarda Hosp, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois-Xavier","family":"Blanc8","sequence":"additional","affiliation":[{"name":"8. Nantes Universit\u00e9, CHU Nantes, Service de Pneumologie, l'institut du thorax, Nantes, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Tiberi9","sequence":"additional","affiliation":[{"name":"9. Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"W M Ong10,11,12","sequence":"additional","affiliation":[{"name":"10. Infectious Diseases Translational Research Programme, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 11. Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore. 12. Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Heffernan13","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Sotgiu14","sequence":"additional","affiliation":[{"name":"14. Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosella","family":"Centis3","sequence":"additional","affiliation":[{"name":"3. Istituti Clinici Scientifici Maugeri - IRCCS - Tradate, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Caroline Dobler1,2","sequence":"additional","affiliation":[{"name":"1. University of New South Wales, Sydney, Australia. 2. The George Institute for Global Health, Sydney, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"The Global Tuberculosis","family":"Network","sequence":"additional","affiliation":[{"name":"Others"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.           Migliori GB, Ong CWM, Petrone L, D\u2019Ambrosio L, Centis R, Goletti D. The definition of tuberculosis infection based on the spectrum of tuberculosis disease. Breathe (Sheff). 2021;17(3):210079. https:\/\/doi.org\/10.1183\/20734735.0079-2021","DOI":"10.1183\/20734735.0079-2021"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.           Ritter J, Flower RJ, Henderson G, Loke YK, MacEwan D, Rang HP. Rang & Dale\u2019s Pharmacology. Endinburgh: Elsevier; 2020.","DOI":"10.1016\/b978-0-443-06911-6.50020-7"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.           Ai JW, Zhang S, Ruan QL, Yu YQ, Zhang BY, Liu QH, et al. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-a Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry\/Cohort Studies. J Rheumatol. 2015;42(12):2229-2237. https:\/\/doi.org\/10.3899\/jrheum.150057","DOI":"10.3899\/jrheum.150057"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.           Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Br\u00e9ban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry [published correction appears in Arthritis Rheum. 2009 Aug;60(8):2540. Lorthololary, O [corrected to Lortholary, O]]. Arthritis Rheum. 2009;60(7):1884-1894. https:\/\/doi.org\/10.1002\/art.24632","DOI":"10.1002\/art.24632"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.           Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-a (TNF-a) targeted biologics and recently licensed TNF-a inhibitors: data from clinical trials and national registries. J Rheumatol Suppl. 2014;91:56-64. https:\/\/doi.org\/10.3899\/jrheum.140103","DOI":"10.3899\/jrheum.140103"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.           Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, Kvien TK, Sandborn WJ, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019;5(1):e000942. https:\/\/doi.org\/10.1136\/rmdopen-2019-000942","DOI":"10.1136\/rmdopen-2019-000942"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.           Simon TA, Dong L, Winthrop KL. Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data. Arthritis Res Ther. 2021;23(1):17. https:\/\/doi.org\/10.1186\/s13075-020-02399-2","DOI":"10.21203\/rs.3.rs-16479\/v2"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.           Evangelatos G, Koulouri V, Iliopoulos A, Fragoulis GE. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis. 2020;12:1759720X20930116. https:\/\/doi.org\/10.1177\/1759720X20930116","DOI":"10.1177\/1759720x20930116"},{"key":"ref8","unstructured":"9.           Alkadi A, Alduaiji N, Alrehaily A. Risk of tuberculosis reactivation with rituximab therapy. Int J Health Sci (Qassim). 2017;11(2):41-44."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.        Shobha V, Chandrashekara S, Rao V, Desai A, Jois R, Dharmanand BG, et al. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India. Int J Rheum Dis. 2019;22(2):280-287. https:\/\/doi.org\/10.1111\/1756-185X.13376","DOI":"10.1111\/1756-185x.13376"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.        Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators Inflamm. 2017;2017:8909834. https:\/\/doi.org\/10.1155\/2017\/8909834","DOI":"10.1155\/2017\/8909834"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.        Liu AY. Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition. Infect Dis Clin North Am. 2020;34(2):211-234. https:\/\/doi.org\/10.1016\/j.idc.2020.02.003","DOI":"10.1016\/j.idc.2020.02.003"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.        Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24 Suppl 2:S21-S40. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.002","DOI":"10.1016\/j.cmi.2018.02.002"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.        Dobler CC. Biologic Agents and Tuberculosis. Microbiol Spectr. 2016;4(6):10.1128\/microbiolspec.TNMI7-0026-2016. https:\/\/doi.org\/10.1128\/microbiolspec.TNMI7-0026-2016","DOI":"10.1128\/microbiolspec.tnmi7-0026-2016"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.        Campbell C, Andersson MI, Ansari MA, Moswela O, Misbah SA, Klenerman P, et al. Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era. Front Med (Lausanne). 2021;8:706482. https:\/\/doi.org\/10.3389\/fmed.2021.706482","DOI":"10.3389\/fmed.2021.706482"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.        Kelsey A, Chirch LM, Payette MJ. Tuberculosis and interleukin blocking monoclonal antibodies: Is there risk?. Dermatol Online J. 2018;24(9):13030\/qt58j4n38m. https:\/\/doi.org\/10.5070\/D3249041425","DOI":"10.5070\/d3249041425"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.        Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, D\u00f6rner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-920. https:\/\/doi.org\/10.1136\/ard.2010.144998","DOI":"10.1136\/ard.2010.144998"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.        Romiti R, Valenzuela F, Chouela EN, Xu W, Pangallo B, Moriarty SR, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis. Br J Dermatol. 2019;181(1):202-203. https:\/\/doi.org\/10.1111\/bjd.17604","DOI":"10.1111\/bjd.17604"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.        Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1449-1456. https:\/\/doi.org\/10.1111\/jdv.16254","DOI":"10.1111\/jdv.16254"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.        Lee EB. A review of sarilumab for the treatment of rheumatoid arthritis. Immunotherapy. 2018;10(1):57-65. https:\/\/doi.org\/10.2217\/imt-2017-0075","DOI":"10.2217\/imt-2017-0075"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.        Silva DR, Rendon A, Alffenaar JW, Chakaya JM, Sotgiu G, Esposito S, et al. Global TB Network: working together to eliminate tuberculosis. J Bras Pneumol. 2018;44(5):347-349. https:\/\/doi.org\/10.1590\/s1806-37562018000000279","DOI":"10.1590\/s1806-37562018000000279"},{"key":"ref21","unstructured":"22.        World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/363752\/9789240061729-eng.pdf?sequence=1"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.        Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14(6):503-509. https:\/\/doi.org\/10.1016\/j.autrev.2015.01.011","DOI":"10.1016\/j.autrev.2015.01.011"},{"key":"ref23","unstructured":"24.        Federatie Medisch Specialisten [homepage on the Internet]. Utrecht: Federatie Medisch Specialiste; [updated 2019 Apr 15; cited 2023 May 1]. Risico-inventarisatie op latente tbc-infectie. Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/tbc-screening_immuunsuppressiva\/risico-inventarisatie_op_latente_tbc-infectie.html"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.        Diel R, Schaberg T, Nienhaus A, Otto-Knapp R, Kneitz C, Krause A, et al. Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals. Pneumologie. 2021;75(4):293-303. https:\/\/doi.org\/10.1055\/a-1294-1580","DOI":"10.1055\/a-1294-1580"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.        Migliori GB, Dowdy D, Denholm JT, D\u2019Ambrosio L, Centis R. The path to tuberculosis elimination: a renewed vision. Eur Respir J. 2023;61(6):2300499. https:\/\/doi.org\/10.1183\/13993003.00499-2023","DOI":"10.1183\/13993003.00499-2023"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.        Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol. 2010;161(1):1-9. https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04146.x","DOI":"10.1111\/j.1365-2249.2010.04146.x"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.        Migliori GB, Wu SJ, Matteelli A, Zenner D, Goletti D, Ahmedov S, et al. Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis. 2022;26(3):190-205. https:\/\/doi.org\/10.5588\/ijtld.21.0753","DOI":"10.5588\/ijtld.22.0452"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.        Mir Viladrich I, Daud\u00e9n Tello E, Solano-L\u00f3pez G, L\u00f3pez Longo FJ, Taxonera Samso C, S\u00e1nchez Mart\u00ednez P, et al. Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment. Arch Bronconeumol. 2016;52(1):36-45. https:\/\/doi.org\/10.1016\/j.arbres.2015.04.016","DOI":"10.1016\/j.arbr.2015.11.005"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.        Mikulska M, Lanini S, Gudiol C, Drgona L, Ippolito G, Fern\u00e1ndez-Ruiz M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24 Suppl 2:S71-S82. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.003","DOI":"10.1016\/j.cmi.2018.02.003"},{"key":"ref30","unstructured":"31.        Rodriguez I.I, Zamarbide OG. Risk of Infection Associated with Biological Agents Used for Autoimmune Inflammatory Diseases. Drug Therapeut Bull Navarre. 2020;20(3):1-16."},{"key":"ref31","unstructured":"32.        White A, Terry L. Guideline for Tuberculosis screening for Biologic and Immunomodulatory drugs for inflammatory conditions. Glocester: NHS Glocestershere Hospitals; 2023. Available from: https:\/\/www.gloshospitals.nhs.uk\/media\/documents\/TB_screening_for_Biologic_and_Immunomodulatory_drugs_October_2023.pdf"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.        Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935-952. https:\/\/doi.org\/10.1164\/rccm.200510-1666ST","DOI":"10.1164\/rccm.200510-1666st"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T15:49:52Z","timestamp":1726674592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jornaldepneumologia.com.br\/details\/3999\/en-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":33,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20240082","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]}}}